Risk Stratification for Allogeneic Transplantation in Myelofibrosis: MTSS versus AlloRisk and the Impact of Driver Mutation Clearance (ICBMT 2026) - Oct 8, 2026 - Abstract #OP06-1; Pres time: Sep 18, 2026; 09:00 AM - 09:10 AM; Location: Room B(1F); "Most patients (80%) received ruxolitinib before transplantation and reduced-intensity conditioning (82.7%)... MTSS and AlloRisk demonstrated comparable discrimination but limited concordance in this contemporary Asian MF transplant cohort. Day-30 driver mutation clearance provided additional prognostic information, particularly among higher-risk patients. Larger prospective studies using standardized molecular assays and landmark analyses are warranted."
Bone Marrow Transplantation • Myelofibrosis • Transplantation • JAK2
|
|
Yu-Sung Chang 1, 2, 3; Xavier Cheng-Hong Tsai 1; Tai-Chung Tseng 1; Yu-Hung Wang 4; Jia-Hau Liu 4; Chien-Chin Lin 1, 5; Chang-Tsu Yuan 6; Wan-Hsuan Lee 1, 2, 3; Feng-Ming Tien 1; Sze-Hwei Lee 1, 7; Bor-Sheng Ko 1, 4; Ming Yao 1, 7; Hwei-Fang Tien 1, 8; Wen-Chien Chou 1; Hsin-An Hou 1, 2
|